Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Престариум А в лечении артериальной гипертензии и пациентов высокого риска: почему ему отдается предпочтение?
Престариум А в лечении артериальной гипертензии и пациентов высокого риска: почему ему отдается предпочтение?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Berthet K, Neal BC, Chalmers JP et al. Perindopril Protection Against Recurrent Stroke Study ollaborative Group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004; 13: 7–13.
2. Bo..hlen L, Bienz R, Doser M et al. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol 1996; 27 (6): 770–6.
3. Ceconi C, Fox KM, Remme WJ et al. EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
4. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–45.
5. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:–895–906.
6. Daly CA, Fox KM, Remme WJ et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
7. Ferrari R, Pasanisi G, Notarstefano P et al. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3: 15–29.
8. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166: 659–66.
9. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators/Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
10. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6.
11. Hughes AD, Thurston H, O’Rourke M. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
12. Jerums G, Allen TJ, Campbell DJ et al. Melbourne Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabet Med 2004; 21: 1192–9.
13. Kool MJ, Lustermans FA, Breed JG et al. The influence of perindopril and the diuretic combination amiloride hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13: 839–48.
14. Myers MG. A dose–response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose–Response Study Group. Can J Cardiol 1996; 12: 1191–6.
15. Poulter NR, Wedel H, Dahlof B et al. ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 005; 366.
16. Safar ME. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens Suppl 1988; 6: S33–9.
17. Sihm I, Schroeder AP, Aalkjaer C et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE inhibitor perindopril. Blood Press 1995; 4: 241–8.
18. Telejko E. Perindopril–arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007; 23: 953–60.
19. Карпов Ю.А., Шальнова С.А., Деев А.Д. (от имени участников программы ПРЕМЬЕРА). Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология. 2006; 6: 32–8.
20. Мычка В.Б., Чазова И.Е. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артер. гипертен. 2002; 8: 36–41.
21. Шальнова С.А., Деев А.Д., Карпов Ю.А. (от имени участников программы ПРЕМЬЕРА). Артериальная гипертония и ИБС в амбулаторной практике врача-кардиолога. Кардиоваск. тер. и проф. 2006; 5 (2): 73–80.
2. Bo..hlen L, Bienz R, Doser M et al. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol 1996; 27 (6): 770–6.
3. Ceconi C, Fox KM, Remme WJ et al. EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
4. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–45.
5. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:–895–906.
6. Daly CA, Fox KM, Remme WJ et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
7. Ferrari R, Pasanisi G, Notarstefano P et al. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3: 15–29.
8. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166: 659–66.
9. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators/Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
10. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6.
11. Hughes AD, Thurston H, O’Rourke M. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
12. Jerums G, Allen TJ, Campbell DJ et al. Melbourne Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabet Med 2004; 21: 1192–9.
13. Kool MJ, Lustermans FA, Breed JG et al. The influence of perindopril and the diuretic combination amiloride hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13: 839–48.
14. Myers MG. A dose–response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose–Response Study Group. Can J Cardiol 1996; 12: 1191–6.
15. Poulter NR, Wedel H, Dahlof B et al. ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 005; 366.
16. Safar ME. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens Suppl 1988; 6: S33–9.
17. Sihm I, Schroeder AP, Aalkjaer C et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE inhibitor perindopril. Blood Press 1995; 4: 241–8.
18. Telejko E. Perindopril–arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007; 23: 953–60.
19. Карпов Ю.А., Шальнова С.А., Деев А.Д. (от имени участников программы ПРЕМЬЕРА). Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология. 2006; 6: 32–8.
20. Мычка В.Б., Чазова И.Е. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артер. гипертен. 2002; 8: 36–41.
21. Шальнова С.А., Деев А.Д., Карпов Ю.А. (от имени участников программы ПРЕМЬЕРА). Артериальная гипертония и ИБС в амбулаторной практике врача-кардиолога. Кардиоваск. тер. и проф. 2006; 5 (2): 73–80.
Авторы
С.В.Недогода
Волгоградский государственный медицинский университет
Волгоградский государственный медицинский университет
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.